Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000087533 | SCV002140177 | pathogenic | Ehlers-Danlos syndrome, type 4 | 2022-03-18 | criteria provided, single submitter | clinical testing | This variant disrupts the triple helix domain of COL3A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, variants that affect these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 101295). This variant is also known as G82V. This missense change has been observed in individuals with clinical features of vascular Ehlers-Danlos syndrome (PMID: 10706896; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 249 of the COL3A1 protein (p.Gly249Val). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly249 (also known as G82) amino acid residue in COL3A1. Other variant(s) that disrupt this residue have been observed in individuals with COL3A1-related conditions (PMID: 10706896), which suggests that this may be a clinically significant amino acid residue. |
| Collagen Diagnostic Laboratory, |
RCV000087533 | SCV000120420 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |